No abstract

No abstract

In a placebo-controlled randomized double-blind cross-over study 16 patients with congestive heart failure (NYHA stage II; 12 male and 4 female; age 60.2 ± 9.8 years; body weight 77.8 ± 13.9 kg; X ± SD) received single oral doses of 90 and 180 mg diltiazem sustained release (s.r.) as well as 20 and 40 mg nitrendipine. Systolic time intervals, impedance cardiography, venous occlusion plethysmography, heart rate and blood pressure were measured 3, 6 and 12 h after administration of the drug. In impedance cardiography both dosages of diltiazem s.r. led to a significant increase in stroke volume and the heather index compared with the placebo values. Nitrendipine, on the other hand, only slightly increased these parameters. Cardiac output was not influenced by any of the kinds of treatment. While heart rate was significantly reduced after ingestion of 90 and 180 mg diltiazem s.r., it was accelerated under the influence of nitrendipine. Both calcium channel blockers significantly reduced diastolic blood pressure, but only 180 mg diltiazem s.r. exerted a marked antihypertensive effect on systolic blood pressure. In mechanocardiography the preejection period was shortened after administration of diltiazem and nitrendipine, although this effect was only significant for 180 mg diltiazem s.r. The PEP/LVET ratio was slightly reduced under the four different kinds of treatment; the parameters measured by venous occlusion plethysmography remained unchanged. From the results of the present study it can be concluded that over a 12-hour period of observation 90 and 180 mg diltiazem s.r. exert a more favorable effect on cardiac performance than 20 and 40 mg nitrendipine. By increasing stroke volume and - at the same time - reducing heart rate, diltiazem s.r. enables the left ventricle to work on a more economic base than nitrendipine does.

Background: The incidence of breast cancer is as low as 0.50% in females younger than 40 years old. Young age in patients with breast cancers is thought to be associated with poor prognosis, but the reason is not well defined. Adverse pathological features like more TNBC and Her2 positivity as well as a lack of reliable screening methods in young women leads to the poor prognosis in this group of patients. This study aimed to analyse the prognostic value of age in patients with carcinoma breast. abstractsAnnals of Oncology Volume 31 -Issue S2 -2020 S55

SUMMARY. The antiinflammatory agent oxaprozin did not interact adversely with the antihypertensive properties of metoprolol after 4 weeks of co-therapy. KEY WORDS. oxaprozin, metoprolol, interaction, hypertensives, nonsteroidal antiinflsmmatory drug (NSAID)